Peptides A-Z · Research Guide
This article helps researchers and advanced users evaluate which peptide suppliers are most reliable for nonclinical work. It explains what to request from vendors, how to read a…
Research peptides refers to peptide compounds supplied for laboratory, preclinical, or analytical use rather than for approved clinical treatment, and buyers should treat them as research materials with nonclinical intent. The phrase research peptides will be used throughout to emphasize sourcing and quality checks rather than any therapeutic claim.
The market for peptide therapeutics and research peptides has grown rapidly in recent years, increasing the number of vendors and the variability in quality controls buyers encounter, which makes active vendor vetting more important than before Peptide Therapeutics Market Size & Trends Report 2025. Peptides 101
Poor quality control can undermine experimental reproducibility, waste budgets, and delay projects when a material is mislabeled or contains uncharacterized impurities. Researchers who rely on reproducible assays should treat vendor QC documentation as a core part of experimental planning rather than an optional detail.
Check for a dated COA tied to the batch, orthogonal testing (HPLC plus MS), documented method validation or third-party testing, and clear stability and returns policies before purchasing.
Before you request documents, be clear about the intended use and the level of analytical confidence your experiment requires; the rest of this guide maps those requirements to specific checks you can request from any potential supplier.
Two enduring references set expectations for peptide specifications and analytical method validation: ICH Q6B describes specifications and acceptance criteria for biotechnological products, and FDA bioanalytical method validation guidance outlines method performance elements buyers should ask about. These documents are not purchase contracts, but they are useful standards to cite when requesting method details ICH Q6B guidance. The Q6B guideline is available as a PDF here, and a recent review summarizes regulatory guideline considerations Regulatory Guidelines for the Analysis of Therapeutic ….
ICH Q6B provides a framework for what a specification should cover, such as identity, purity, potency where appropriate, and stability. For research purchases, it can be used as a checklist to ensure a vendor reports test types and acceptance criteria rather than just a single percent purity number.
The FDA guidance on bioanalytical method validation describes method characteristics buyers should ask about when reviewing a COA, including accuracy, precision, specificity, and limits of detection and quantitation. Requesting method validation summaries or statements of method performance helps you understand whether reported values are robust or preliminary FDA bioanalytical guidance.
Regional agencies such as the European Medicines Agency provide complementary scientific guidelines that often mirror ICH and FDA expectations; when a vendor references regional guidance or harmonized documents, it can increase confidence in their procedural standards EMA scientific guidelines. The EMA text for Q6B specifications is available as a guidance PDF ICH Q6B Specifications PDF.
Ask for a dated Certificate of Analysis tied to the specific batch or lot number you will receive. The COA should list the analytical methods used and include identification and purity results. Without a dated COA that matches the lot, it is difficult to confirm that the document applies to the specific material you ordered.
Expect orthogonal evidence: HPLC for purity measurements and mass spectrometry for identity are the common, minimum combination used across the field to support a COA. Where sequence confirmation matters, peptide mapping or amino-acid analysis is a reasonable additional test to request Analytical strategies for characterization and quality control of therapeutic peptides.
Ask vendors to confirm batch traceability information such as manufacturing date, lot number, and any stability or storage data that define shelf life or recommended conditions. This information is often decisive when deciding between similar suppliers because it clarifies how long a batch is expected to remain within specification.
When vendors provide stability data or storage instructions on the COA, it helps you plan receipt and handling to avoid degradation during transit or storage, particularly for peptides that require low-temperature conditions or desiccation.
A typical COA should include a clear lot or batch number, the COA issue or test date, the identity result and method used, a purity percentage and the method used to determine it, and any stability or storage notes. Each of these fields answers a specific verification need: lot number ties the document to a shipment, methods show how results were obtained, and dates and stability notes reveal usability windows.
If a COA is undated or not tied to a batch, treat that as a significant gap; such COAs are common omissions and reduce the document’s reliability as proof that a specific material was tested.
HPLC is commonly used to estimate purity by separating components and reporting an assay percent based on peak area. Mass spectrometry provides mass confirmation and supports identity claims by matching molecular mass or fragment patterns. Amino-acid analysis or peptide mapping provides sequence-level confirmation and better impurity profiling when identity and sequence are critical Custom peptide synthesis: QC, methods and choosing a supplier.
Reading a COA method section, look for method names, brief descriptions, and any numerical acceptance criteria. If a method is listed without performance parameters, follow up and request validation summaries or at least statements of accuracy and precision.
COAs should specify storage temperature and any protected-from conditions, such as light or humidity. These fields help you decide whether the vendor handled the material appropriately and whether you need cold chain shipping or special packing on receipt.
Absence of storage or stability details is a practical red flag because it leaves the buyer guessing about shelf life and appropriate handling during transit.
Start by emailing a concise list of questions to the vendor that request the COA, method names and validation status, and batch traceability information. Keep questions factual and linked to your lab requirements so the vendor can respond with specific files or statements rather than marketing language.
If a vendor claims validated methods or external lab testing, ask for the validation summary or the independent lab report. Independent third-party testing from an ISO/IEC 17025 accredited laboratory provides stronger confidence in identity and purity than vendor-only COAs when available FDA bioanalytical guidance.
Keep written records of vendor responses and attach any COAs to your procurement file; this creates an audit trail that helps if you later need to reconcile batch behavior with experimental results. Maintaining a simple file per lot number saves time and reduces confusion in multi-batch projects.
On receipt of material perform simple physical checks: confirm packaging integrity, any cold pack condition, and that the lot number on the container matches the COA. Those quick checks can often flag shipping or labeling mistakes before you open and use the compound.
Missing or undated COAs tied to batches are a primary red flag. If you cannot confirm that the COA corresponds to your lot, treat the material as unverified and consider requesting retesting or proof of traceability from the vendor.
Beware vendors that only provide a single purity percentage without identity confirmation. Purity alone does not confirm the compound’s sequence or identity, and single-method claims are insufficient for experiments where identity matters Analytical strategies for characterization and quality control of therapeutic peptides.
Vague or absent returns and remediation policies reduce buyer recourse if a shipment does not match its COA. Ask vendors to state their returns policy and any remediation steps clearly before ordering to avoid surprises later. See our guide on how to find a legitimate peptide provider.
Scenario 1: ordering a small screening batch for exploratory lab work. For low-risk screening you may accept a COA with HPLC purity and vendor MS identity confirmation, provided the lot number and date are present and the vendor documents storage conditions.
Scenario 2: sourcing a peptide for method development where sequence confirmation is essential. In that case, require peptide mapping or amino-acid analysis on the COA and consider third-party confirmation before committing to large-scale use Custom peptide synthesis: QC, methods and choosing a supplier.
Scenario 3: when to pause and request third-party testing. If the vendor cannot provide a dated COA tied to the batch or offers only single-method purity without identity confirmation, the cost of independent ISO/IEC 17025 lab testing is often justified by the risk of wasted experiments or misinterpretation.
Each scenario balances cost and risk. For quick screens the minimum documented evidence may be sufficient, while sequence-sensitive or regulatory-adjacent work often justifies higher verification costs.
Quick recap checklist: request a dated COA tied to the lot, ensure orthogonal testing is documented (HPLC plus MS), ask for method validation summaries or statements, and record stability and storage conditions before ordering. These items are the minimal documentation set that meaningfully reduces procurement risk.
Prioritized next steps: ask the vendor the checklist questions, request third-party testing when identity or impurity profiling is critical, and perform basic receipt checks against the COA on arrival. Remember that this guide focuses on sourcing and verification for research purposes and does not provide clinical or medical advice ICH Q6B guidance. See medical-grade vs research-grade peptides.
Request a dated COA tied to the specific batch, the analytical methods used, any method validation summaries or statements, and documented stability or storage conditions.
Third-party ISO/IEC 17025 testing is justified when sequence confirmation, impurity profiling, or high downstream risk means vendor documentation alone is insufficient.
No, purity alone is insufficient; identity confirmation such as mass spectrometry and, where needed, peptide mapping should accompany purity results.
Bottom line
Use the checklist and verification steps in this guide to make procurement decisions that match your experimental risk. Keep all vendor communications and COAs with your lab records so you can trace any issues back to a specific lot.
The 2-minute quiz sorts the research by what you actually want to achieve, then points you to the guides that apply to you.